Detailed Information
Cited 17 time in 
Cited 0 time in 
Cited 0 time in
Metadata Downloads
BAYOU: A phase II, randomized, multicenter, double-blind, study of durvalumab (D) in combination with olaparib (O) for the first-line treatment of platinum-ineligible patients with unresectable, stage IV urothelial carcinoma (UC).
- Authors
- Rosenberg, JE[Rosenberg, Jonathan E.]; Park, SH[Park, Se Hoon]; Dao, TV[Dao, Tu V.]; Castellano, DE[Castellano, Daniel E.]; Li, JR[Li, Jian-Ri]; Mukherjee, S[Mukherjee, Som]; Howells, K[Howells, Kathryn]; Dry, H[Dry, Hannah]; Lanasa, MC[Lanasa, Mark C.]; Stewart, R[Stewart, Ross]; Bajorin, DF[Bajorin, Dean F.]
- Issue Date
- 20-Feb-2022
- Publisher
- LIPPINCOTT WILLIAMS & WILKINS
- Citation
- JOURNAL OF CLINICAL ONCOLOGY, v.40, no.6
- Indexed
- SCIE
SCOPUS
- Journal Title
- JOURNAL OF CLINICAL ONCOLOGY
- Volume
- 40
- Number
- 6
- ISSN
- 0732-183X
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - Medicine > Department of Medicine > 1. Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.